836 results about "SAPS II" patented technology

A system and method for providing an accurate root cause failure by linking user incident reports to the root cause failure in a diagnostic database that reflects the system's current configuration. The system is pre-populated with pre-identified symptoms that are associated with assets in the system. The pre-identified symptoms are inactive until actual failures with assets are detected by a monitoring application. After the pre-identified symptoms become active, they are presented to service representatives who also answer calls from users. The activated pre-identified symptoms are used to assist the service representatives to solve problems observed by the users.

A neurological control system for modulating activity of any component or structure comprising the entirety or portion of the nervous system, or any structure interfaced thereto, generally referred to herein as a “nervous system component.” The neurological control system generates neural modulation signals delivered to a nervous system component through one or more intracranial (IC) stimulating electrodes in accordance with treatment parameters. Such treatment parameters may be derived from a neural response to previously delivered neural modulation signals sensed by one or more sensors, each configured to sense a particular characteristic indicative of a neurological or psychiatric condition.

This patent document discusses, among other things, systems, devices, and methods for enhancing detection of pulmonary edema using, in addition to thoracic impedance, one or a combination of: physiologic information about a subject, at least one statistical parameter, a user-programmable detection level, at least one parameter associated with a previous pulmonary edema event, and patient symptom information about the subject. In one example, a (base) thoracic impedance threshold is modified to an adjusted thoracic impedance threshold. The adjusted thoracic impedance threshold provides an increased sensitivity of pulmonary edema detection as compared to the base thoracic impedance threshold. In another example, an alert is provided to a subject, a caregiver, or other user based on a pulmonary edema indication determined by the present systems, devices, and methods. In a further example, a therapy (provided to the subject) is adjusted or initiated in response to the pulmonary edema indication.

A system and method is provided in which medical treatment of a patient is effected in a systematic and guided fashion. From a patient's symptoms and electronic medical record, a specific diagnostic test may be recommended. Upon execution of the diagnostic test, the diagnostic scan results may be forwarded to a remote location for assistance in analysis. Once analyzed, the results are transmitted to the attending medical personnel. The results, and information which led to the decision to have a diagnostic test, are also sent to a repository for use in future diagnoses and other determinations. A monitor or dashboard is used to keep track of the various steps of the procedure, to provide on the job guidance in using a diagnostic test device, and the ensure a specific efficiency and protocol are followed. A remote location of experts may also be monitoring the dashboard, as a quality control.

A method is disclosed for detecting symptoms in a network infrastructure, combining one or more symptoms into a problem, then optionally applying detailed diagnosis to the network elements experiencing the problems, ultimately providing detailed problem determination.

A method useful for facilitating choosing a treatment or treatment regime and for predicting the outcome of a treatment for a disorder which is diagnosed and monitored by a physician or other appropriately trained and licensed professional, such as for example, a psychologist, based upon the symptoms experienced by a patient. Unipolar depression is an example of such a disorder, however the model may find use with other disorders and conditions wherein the patient response to treatment is variable. In the preferred embodiment, the method for predicting patient response includes the steps of performing at least one measurement of a symptom on a patient and measuring that symptom so as to derive a baseline patient profile, such as for example, determining the symptom profile with time; defining a set of a plurality of predictor variables which define the data of the baseline patient profile, wherein the set of predictor variables includes predictive symptoms and a set of treatment options; deriving a model that represents the relationship between patient response and the set of predictor variables; and utilizing the model to predict the response of said patient to a treatment. A neural net architecture is utilized to define a non-linear, second order model which is utilized to analyze the patient data and generate the predictive database from entered patient data.

An expert diagnostic service system using a distributed architecture for generating expert diagnostic suggestions based on input received from a plurality of diagnostic systems. The expert service system collects data related to effective diagnostic results, such as effective fixes, corresponding to various symptoms / faults from a plurality of diagnostic systems via a data transmission network, and accumulates the number of each effective fix corresponding to each of the various symptoms. The expert service system then assigns at least one effective fix to one of the various symptoms based on a result of the accumulating step, such as the rank of the accumulated number of each fix. The expert service system uses the assigned fix corresponding to a symptom as expert suggestions.

This invention defines a novel method for treatment of several neurological diseases and pathophysiologically related symptomology, said diseases including peripheral neuropathies, secondary symptomology of diabetes, Alzheimer's disease, Parkinson's disease, alcoholic polyneuropathy and age-onset symptomology, as well as analogous veterinary disease states. An opportunity exists for pharmacological intervention in some neurological diseases by use of water soluble, small molecular weight primary amine agents and chemical derivatives thereof. Examples of such primary pharmacological agents include 4-aminobenzoic acid and derivatives thereof. The present invention also includes: (1) oral use of optional non-absorbable polyamine polymeric co-agents such as chitosan, (2) oral use of optional known antioxidant co-agents and nutritional factors related thereto, and (3) use of the primary agents and co-agents noted above in optional combination with medicaments recognized as effective for treatment of the diseases addressed herein or symptoms thereof.

For Parkinson's patients to function at their best, their medications need to be optimally adjusted to the diurnal variation of symptoms. For this to occur, it is important for the managing clinician to have an accurate picture of how the patient's bradykinesia / hypokinesia and dyskinesia and the patient's perception of movement state fluctuate throughout the normal daily activities. The present invention uses wearable accelerometers coupled with computer implemented learning and statistical analysis techniques in order to classify the movement states of Parkinson's patients and to provide a timeline of how the patients fluctuate throughout the day.

A computer implemented method on a computer readable media is provided for determining the source of a problem in a complex system of managed components based upon symptoms. The problem source identification process is split into different activities. Explicit configuration non-specific representations of types of managed components, their problems, symptoms and the relations along which the problems or symptoms propagate are created that can be manipulated by executable computer code. A data structure is produced for determining the source of a problem by combining one or more of the representations based on information of specific instances of managed components in the system. Computer code is then executed which uses the data structure to determine the source of the problem from one or more symptoms.

The present invention relates to the intrathecal (IT) administration of recombinant enzyme to treat lysosomal storage disorders. In an exemplary embodiment, intrathecal administration of human α-L-iduronidase (rhIDU) injections in MPS I affected animals resulted in significant enzyme uptake, significant rh-iduronidase activity in brain and meninges and a decrease of glycosaminoglycan (GAG) storage in cells of MPS I subjects to that of normal subjects. Intrathecal administration proved more effective than intravenous treatment at alleviating MPS I symptoms, indicating it is a useful method of treating lysosomal storage disorders.

Characterization of carotid atherosclerosis and classification of plaque into symptomatic or asymptomatic along with the risk score estimation are key steps necessary for allowing the vascular surgeons to decide if the patient has to definitely undergo risky treatment procedures that are needed to unblock the stenosis. This application describes a statistical (a) Computer Aided Diagnostic (CAD) technique for symptomatic versus asymptomatic plaque automated classification of carotid ultrasound images and (b) presents a cardiovascular stroke risk score computation. We demonstrate this for longitudinal Ultrasound, CT, MR modalities and extendable to 3D carotid Ultrasound. The on-line system consists of Atherosclerotic Wall Region estimation using AtheroEdge™ for longitudinal Ultrasound or Athero-CTView™ for CT or Athero-MRView from MR. This greyscale Wall Region is then fed to a feature extraction processor which computes: (a) Higher Order Spectra; (b) Discrete Wavelet Transform (DWT); (c) Texture and (d) Wall Variability. The output of the Feature Processor is fed to the Classifier which is trained off-line from the Database of similar Atherosclerotic Wall Region images. The off-line Classifier is trained from the significant features from (a) Higher Order Spectra; (b) Discrete Wavelet Transform (DWT); (c) Texture and (d) Wall Variability, selected using t-test. Symptomatic ground truth information about the training patients is drawn from cross modality imaging such as CT or MR or 3D ultrasound in the form of 0 or 1. Support Vector Machine (SVM) supervised classifier of varying kernel functions is used off-line for training. The Atheromatic™ system is also demonstrated for Radial Basis Probabilistic Neural Network (RBPNN), or Nearest Neighbor (KNN) classifier or Decision Trees (DT) Classifier for symptomatic versus asymptomatic plaque automated classification. The obtained training parameters are then used to evaluate the test set. The system also yields the cardiovascular stroke risk score value on the basis of the four set of wall features.

A method and system for providing rectangular and / or complex electrical pulses to cortical tissues of a patient for providing therapy or alleviating symptoms for at least one of tinnitus, essential tremor (ET) including Parkinson's disease, depression, or for providing improvement of functional recovery following stroke. The intracranial electrodes may be implanted on the dura, or subdurally on the pia mater of the cortical surface. The placement of the electrodes may utilize cortical sensing and / or digital imaging techniques, such as fMRI, MRI, or CT. The pulse generator system comprises implantable and external components. The pulse generator may be an implanted pulse generator (IPG) or an external stimulator coupled with an implanted stimulus-receiver. The IPG may also comprise a rechargeable battery. In one embodiment the pulse generator may also comprise a selected number of predetermined / pre-packaged programs. In one embodiment, the pulse generation may also comprise telemetry means, for remote interrogation and / or programming of said pulse generator utilizing a wide area network, such as the internet.

The invention features methods, systems, and computer programs for generating a customized set of possible medical conditions, thereby providing access to medical information relevant to the user's state of health. The methods and systems involve at least some of the following steps: receiving a list of symptoms specified in terms selected from a first language set; translating the list of symptoms into a translated list of symptoms specified in terms selected from a second language set; using the translated list of symptoms to generate possible medical conditions, the possible medical conditions described in terms of the second language set; and translating the possible medical conditions into descriptions that are specified in terms selected from the first language set.

A system and method for providing computerized, knowledge-based medical diagnostic and treatment advice. The medical advice is provided to the general public over a telephone network. Two new authoring languages, interactive voice response and speech recognition are used to enable expert and general practitioner knowledge to be encoded for access by the public. “Meta” functions for time-density analysis of a number of factors regarding the number of medical complaints per unit of time are an integral part of the system. A semantic discrepancy evaluator routine along with a mental status examination are used to detect the consciousness level of a user of the system. A re-enter feature monitors the user's changing condition over time. A symptom severity analysis helps to respond to the changing conditions. System sensitivity factors may be changed at a global level or other levels to adjust the system advice as necessary.

A computer implemented and interactive system for obtaining a patient's symptoms and other indications of disease, which are utilized to determine the probable existence of disease. The program generates a series of inquiries which are displayed to a patient who is asked to identify the body part which the patient believes is causing a physical or mental problem. The system's program uses a database of diseases and related symptoms to generate questions. Based upon the patient's answer to each question, the program determines the probability that the patient has one of the diseases contained in the database. When the patient has completed answering all of the questions, the system's program generates a report of the probable existence diseases, including the patient's most probable disease.

Provided are compositions and methods for treating lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis, and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically altered fluid (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures as disclosed herein. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (e.g., membrane receptors, (e.g., to G protein coupled receptors, and intercellular junctions)). Additional aspects include therapeutic compositions, and combination treatment methods comprising administration of electrokinetically generated fluid in combination with at least one additional therapeutic agent.

Autonomous personal service robot to monitor its owner for symptoms of distress and provide assistance. The system may include sensors to detect situations before they affect people such as smoke, heat, temperature and carbon monoxide sensors. The system can provide security for the home. The PRA may comprise features such as a medicine dispenser and blood pressure cuff. Features such as broadband internet, MP3 player, reading lights and eye glass tracker provide butler type capabilities that enable the system to appeal to markets beyond the elderly and infirmed. The system may also include an X10 transmitter / receiver to automatically control various household lights and appliances. Equipping the system with a robot arm enables the robot to fetch items, turn on and off wall switches and open the refrigerator.

A treatment method is disclosed for treating a bodily tissue utilizing one or more steps of removal of material as well as one or more steps of energy delivery in order to effectively treat the bodily tissue. These mechanisms of treatment may beneficially be used to induce separate treatment effects, for example to treat both the symptoms and the underlying cause of a specific pathological condition. In addition, a specific application of the inventive method is described for using the inventive method to treat an intervertebral disc.

The present invention is directed to the development of a biosensor based on the immuno-chromatographic method that can provide an assay speed and convenience required for point-of-care (the doctor's office and emergency room) testing or home-version diagnosis. Though certain physical symptoms, such as pregnancy and ovulation, or bacterial infection may be identified by a qualitative analysis for the presence of indicating substances, most analytes for clinical investigation demand their concentrations known in specimens. Therefore, the inventors of the present invention have developed a novel biosensor by combining the immuno-chromatographic method and the electric conductivity detection technology so that on-site quantitative determination at the points of care or at home may be carried out.

A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms of acute or chronic cardiac insult or impaired cardiac performance. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and / or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with cardiac insult or impaired cardiac performance and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist (e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine).

The present invention relates to a movement disorder monitor, and a method of measuring the severity of a subject's movement disorder. The present invention additionally relates to a drug delivery system for dosing a subject in response to the increased severity of a subject's symptoms. The present invention provides for a system and method, which can accurately quantify symptoms of movements disorders, accurately quantifies symptoms utilizing both kinetic information and electromyography (EMG) data, that can be worn continuously to provide continuous information to be analyzed as needed by the clinician, that can provide analysis in real-time, that allows for home monitoring of symptoms in subject's with these movement disorders to capture the complex fluctuation patterns of the disease over the course of days, weeks or months, that maximizes subject safety, and that provides remote access to the clinician or physician.

The system and process of the present invention employs encrypted data input from both users and physicians to identify disturbances in human biologic function. Physical and metabolic characteristics, historical data and current symptoms are compiled through use of a computerized expert system that recognizes patterns predictive of metabolic dysfunction or insufficiency. Functional capabilities of all bodily systems are simultaneously evaluated at each input session through expert system analysis to create science-based remedial plans exemplifying methods of lifestyle alteration and biologic response modification through nutrition and other means. Enhancement of metabolic activity is presumed on the basis of improving symptom, metabolic, and laboratory scores. Lifestyle, fitness, nutritional, and dietary plans are formatted for uncomplicated implementation and professional guidance in applying all interventions to uniquely integrate the offerings of medical, healthcare and lifestyle professionals.